Results 1 to 10 of about 26,054 (188)
Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study. [PDF]
PLoS Neglected Tropical DiseasesBackgroundPrimaquine (PQ) is the only widely available drug that eliminates latent hypnozoites, thereby preventing relapses of Plasmodium vivax malaria. Because PQ biotransformation mediated by the cytochrome P-450 (CYP) isoenzyme CYP2D6 is required for ...
Rodrigo M Corder +8 more
doaj +2 more sources
Village malaria workers for the community-based management of vivax malaria
The Lancet Regional Health - Southeast Asia, 2023 Summary: In Cambodia, malaria cases are on a trajectory towards the goal of malaria elimination by 2025. Vivax malaria is difficult to eliminate because of hypnozoites that can cause relapse.
Bipin Adhikari +6 more
doaj +1 more source
Vivax Malaria Presenting with Myelitis: A Rare Complication [PDF]
Journal of Clinical and Diagnostic Research, 2013 Neurological complications may occur with the Plasmodium falciparum infection. However, the association of neurological manifestations with vivax malaria remains doubtful. Of late, there are isolated case reports/studies which have implicated P.
Avijit Moulick +4 more
doaj +1 more source
Rising report of Plasmodium vivax in sub-Saharan Africa: Implications for malaria elimination agenda
Scientific African, 2020 Plasmodium vivax and P. falciparum are the most important human malaria species. P. falciparum is considered the most virulent and widespread species in sub-Saharan Africa.
Mary Aigbiremo Oboh +5 more
doaj +1 more source
Adequate Primaquine for Vivax Malaria [PDF]
Journal of Travel Medicine, 2006 Treatment of vivax malaria with primaquine prevents the relapse of infection from residual liver stages of the parasite. Inadequate dosage is related to a higher relapse risk.A comparison was made of vivax malaria relapse-prevention treatments with primaquine 22.5 mg or 30 mg daily for 14 days on 146 reports to the Australian Army Central Malaria ...
Kitchener, S. +3 more
openaire +5 more sources
Clinical impact of vivax malaria: A collection review.
PLoS Medicine, 2022 BackgroundPlasmodium vivax infects an estimated 7 million people every year. Previously, vivax malaria was perceived as a benign condition, particularly when compared to falciparum malaria.
Aung Pyae Phyo +3 more
doaj +1 more source
The anaemia of Plasmodium vivax malaria [PDF]
Malaria Journal, 2012 Plasmodium vivax threatens nearly half the world's population and is a significant impediment to achievement of the millennium development goals. It is an important, but incompletely understood, cause of anaemia. This review synthesizes current evidence on the epidemiology, pathogenesis, treatment and consequences of vivax-associated anaemia.
Douglas, Nicholas +6 more
openaire +4 more sources
Insights into the elimination of vivax malaria in China
Infectious Diseases of Poverty, 2023 Background Malaria is caused by multiple parasitic species of the genus Plasmodium. Plasmodium vivax is the most geographically widespread and poses challenges in elimination due to its unique biological and epidemiological characteristics.
Fang Huang, Li Zhang, Zhi-Gui Xia
doaj +1 more source
Plasmodium vivax Hospitalizations in a Monoendemic Malaria Region: Severe Vivax Malaria? [PDF]
The American Society of Tropical Medicine and Hygiene, 2014 Severe malaria caused by Plasmodium vivax is no longer considered rare. To describe its clinical features, we performed a retrospective case control study in the subregion of Luciano Castillo Colonna, Piura, Peru, an area with nearly exclusive vivax malaria transmission.
Quispe, Antonio M. +7 more
openaire +3 more sources
Vivax Malaria: Neglected and Not Benign [PDF]
The American Journal of Tropical Medicine and Hygiene, 2007 Plasmodium vivax threatens almost 40% of the world’s population, resulting in 132–391 million clinical infections each year. Most of these cases originate from Southeast Asia and the Western Pacific, although a significant number also occurs in Africa and South America.
Price, R +5 more
openaire +4 more sources